HealthCare Royalty Partners
Overview
HealthCare Royalty Partners ("HCR") is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCR has raised over $6.2 billion in cumulative c…
Investment Focus
- Assets with significant clinical value
- Strong barriers to entry
- Sustainable revenues over extended periods
- Alignment with marketer's objectives
Portfolio Companies
Reach HealthCare Royalty Partners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about HealthCare Royalty Partners
What sectors does HealthCare Royalty Partners invest in?
HealthCare Royalty Partners invests in Healthcare, Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology and Specialty Pharmaceuticals, and is based in Stamford, United States. HealthCare Royalty Partners is listed as a private investment firm in the ConnectSafely investor database.
What stage does HealthCare Royalty Partners invest at?
HealthCare Royalty Partners backs companies at Growth, Late Stage and Pre-IPO, writing cheques of 20M - 200M.
Which regions does HealthCare Royalty Partners invest in?
HealthCare Royalty Partners invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
Who are the partners at HealthCare Royalty Partners?
Team members listed for HealthCare Royalty Partners include Carlos Almodovar (Chief Business Officer) and Andrew Reardon (Chief Legal Officer).
What companies has HealthCare Royalty Partners invested in?
HealthCare Royalty Partners's portfolio includes Johnson & Johnson, Ipsen, Bayer AG, CSL Vifor, Maruishi Pharma, Elanco and Bausch Health Companies.
How do I contact HealthCare Royalty Partners?
HealthCare Royalty Partners's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
